T1	Pharmacodynamic_phenotype	28 47	acquired resistance
T2	Gene_or_protein	70 138	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors
T3	Chemical	70 140	epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitors (
T4	Chemical	143 150	I ) for
T5	Disease	174 195	mutant lung cancers .
R1	influences	Arg1:T1	Arg2:T2
R2	influences	Arg1:T1	Arg2:T3
R3	influences	Arg1:T1	Arg2:T4
R4	influences	Arg1:T1	Arg2:T5
R5	treats	Arg1:T2	Arg2:T1
R6	influences	Arg1:T2	Arg2:T3
R7	treats	Arg1:T2	Arg2:T4
R8	treats	Arg1:T2	Arg2:T5
R9	treats	Arg1:T3	Arg2:T1
R10	isEquivalentTo	Arg1:T3	Arg2:T2
R11	treats	Arg1:T3	Arg2:T4
R12	treats	Arg1:T3	Arg2:T5
R13	treats	Arg1:T4	Arg2:T1
R14	isEquivalentTo	Arg1:T4	Arg2:T2
R15	isEquivalentTo	Arg1:T4	Arg2:T3
R16	treats	Arg1:T4	Arg2:T5
R17	isAssociatedWith	Arg1:T5	Arg2:T1
R18	isAssociatedWith	Arg1:T5	Arg2:T2
R19	isAssociatedWith	Arg1:T5	Arg2:T3
R20	isAssociatedWith	Arg1:T5	Arg2:T4
